Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Want to cut your energy bills? Here’s how five experts are doing it 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
NEW YORK, Feb. 27, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Regulus Therapeutics Inc. (NASDAQ:RGLS) securities between January 21, 2016 and June 27, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/regulus-therapeutics. There is no cost or obligation to you.
According to the complaint, throughout the class period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) patients treated with its experimental product RG-101 were at increased risk of contracting jaundice; (ii) consequently, the Company had overstated RG-101’s approval prospects and/or commercial viability; and (iii) as a result of the foregoing, Regulus’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Regulus you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/regulus-therapeutics.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
